HDAC2 attenuates TRAIL-induced apoptosis of pancreatic cancer cells
- PMID: 20398369
- PMCID: PMC2867820
- DOI: 10.1186/1476-4598-9-80
HDAC2 attenuates TRAIL-induced apoptosis of pancreatic cancer cells
Abstract
Background: Pancreatic ductal adenocarcinoma (PDAC) is one of the most malignant tumors with a dismal prognosis and no effective conservative therapeutic strategies. Although it is demonstrated that histone deacetylases (HDACs), especially the class I HDACs HDAC1, 2 and 3 are highly expressed in this disease, little is known about HDAC isoenzyme specific functions.
Results: Depletion of HDAC2, but not HDAC1, in the pancreatic cancer cell lines MiaPaCa2 and Panc1 resulted in a marked sensitization towards the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Correspondingly, the more class I selective HDAC inhibitor (HDACI) valproic acid (VPA) synergized with TRAIL to induce apoptosis of MiaPaCa2 and Panc1 cells. At the molecular level, an increased expression of the TRAIL receptor 1 (DR5), accelerated processing of caspase 8, pronounced cleavage of the BH3-only protein Bid, and increased effector caspase activation was observed in HDAC2-depleted and TRAIL-treated MiaPaCa2 cells.
Conclusions: Our data characterize a novel HDAC2 function in PDAC cells and point to a strategy to overcome TRAIL resistance of PDAC cells, a prerequisite to succeed with a TRAIL targeted therapy in clinical settings.
Figures





Similar articles
-
HDAC2 mediates therapeutic resistance of pancreatic cancer cells via the BH3-only protein NOXA.Gut. 2009 Oct;58(10):1399-409. doi: 10.1136/gut.2009.180711. Epub 2009 Jun 14. Gut. 2009. PMID: 19528037
-
SKP2 confers resistance of pancreatic cancer cells towards TRAIL-induced apoptosis.Int J Oncol. 2011 Jan;38(1):219-25. Int J Oncol. 2011. PMID: 21109943
-
Nuclear death receptor TRAIL-R2 inhibits maturation of let-7 and promotes proliferation of pancreatic and other tumor cells.Gastroenterology. 2014 Jan;146(1):278-90. doi: 10.1053/j.gastro.2013.10.009. Epub 2013 Oct 9. Gastroenterology. 2014. PMID: 24120475
-
Acetylation as a transcriptional control mechanism-HDACs and HATs in pancreatic ductal adenocarcinoma.J Gastrointest Cancer. 2011 Jun;42(2):85-92. doi: 10.1007/s12029-011-9257-1. J Gastrointest Cancer. 2011. PMID: 21271301 Review.
-
Targeting histone deacetylases in pancreatic ductal adenocarcinoma.J Cell Mol Med. 2010 Jun;14(6A):1255-63. doi: 10.1111/j.1582-4934.2009.00974.x. Epub 2009 Nov 19. J Cell Mol Med. 2010. PMID: 19929947 Free PMC article. Review.
Cited by
-
Class 1 Histone Deacetylases and Ataxia-Telangiectasia Mutated Kinase Control the Survival of Murine Pancreatic Cancer Cells upon dNTP Depletion.Cells. 2021 Sep 23;10(10):2520. doi: 10.3390/cells10102520. Cells. 2021. PMID: 34685500 Free PMC article.
-
Possible role of autophagy in the treatment of pancreatic cancer with histone deacetylase inhibitors.Cancers (Basel). 2010 Nov 29;2(4):2026-43. doi: 10.3390/cancers2042026. Cancers (Basel). 2010. PMID: 24281216 Free PMC article.
-
Pancreatic ductal adenocarcinoma: a review of immunologic aspects.J Investig Med. 2012 Apr;60(4):643-63. doi: 10.2310/JIM.0b013e31824a4d79. J Investig Med. 2012. PMID: 22406516 Free PMC article. Review.
-
Histone Deacetylase Inhibitor Panobinostat Benefits the Therapeutic Efficacy of Oncolytic Herpes Simplex Virus Combined with PD-1/PD-L1 Blocking in Glioma and Squamous Cell Carcinoma Models.Viruses. 2022 Dec 15;14(12):2796. doi: 10.3390/v14122796. Viruses. 2022. PMID: 36560800 Free PMC article.
-
HADC regulates the diabetic vascular endothelial dysfunction by targetting MnSOD.Biosci Rep. 2018 Sep 28;38(5):BSR20181042. doi: 10.1042/BSR20181042. Print 2018 Oct 31. Biosci Rep. 2018. PMID: 30217947 Free PMC article.
References
-
- Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25:1960–1966. doi: 10.1200/JCO.2006.07.9525. - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous